Clozapine-induced neuroleptic malignant syndrome

Review and report of new cases

P. Sachdev, J. Kruk, M. Kneebone, D. Kissane

Research output: Contribution to journalArticleResearchpeer-review

Abstract

The published case reports of clozapine-induced neuroleptic malignant syndrome (NMS) are reviewed, to which the authors add three, and possibly four, new cases seen in Australia, occurring in an estimated 1,250 patients exposed to the drug. The review suggests that typical NMS does occur with clozapine and that its incidence may be as common as with the classic neuroleptics. The features of clozapine-induced NMS may be somewhat different, with fewer extrapyramidal side effects and a lower rise in creatine kinase levels. The occurrence of NMS with clozapine raises important issues with regard to our understanding of the pathophysiology of the syndrome.

Original languageEnglish
Pages (from-to)365-371
Number of pages7
JournalJournal of Clinical Psychopharmacology
Volume15
Issue number5
DOIs
Publication statusPublished - 1 Jan 1995

Cite this

@article{2f34534dc2824ebe8b1c0ddc382329ec,
title = "Clozapine-induced neuroleptic malignant syndrome: Review and report of new cases",
abstract = "The published case reports of clozapine-induced neuroleptic malignant syndrome (NMS) are reviewed, to which the authors add three, and possibly four, new cases seen in Australia, occurring in an estimated 1,250 patients exposed to the drug. The review suggests that typical NMS does occur with clozapine and that its incidence may be as common as with the classic neuroleptics. The features of clozapine-induced NMS may be somewhat different, with fewer extrapyramidal side effects and a lower rise in creatine kinase levels. The occurrence of NMS with clozapine raises important issues with regard to our understanding of the pathophysiology of the syndrome.",
author = "P. Sachdev and J. Kruk and M. Kneebone and D. Kissane",
year = "1995",
month = "1",
day = "1",
doi = "10.1097/00004714-199510000-00010",
language = "English",
volume = "15",
pages = "365--371",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams & Wilkins",
number = "5",

}

Clozapine-induced neuroleptic malignant syndrome : Review and report of new cases. / Sachdev, P.; Kruk, J.; Kneebone, M.; Kissane, D.

In: Journal of Clinical Psychopharmacology, Vol. 15, No. 5, 01.01.1995, p. 365-371.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Clozapine-induced neuroleptic malignant syndrome

T2 - Review and report of new cases

AU - Sachdev, P.

AU - Kruk, J.

AU - Kneebone, M.

AU - Kissane, D.

PY - 1995/1/1

Y1 - 1995/1/1

N2 - The published case reports of clozapine-induced neuroleptic malignant syndrome (NMS) are reviewed, to which the authors add three, and possibly four, new cases seen in Australia, occurring in an estimated 1,250 patients exposed to the drug. The review suggests that typical NMS does occur with clozapine and that its incidence may be as common as with the classic neuroleptics. The features of clozapine-induced NMS may be somewhat different, with fewer extrapyramidal side effects and a lower rise in creatine kinase levels. The occurrence of NMS with clozapine raises important issues with regard to our understanding of the pathophysiology of the syndrome.

AB - The published case reports of clozapine-induced neuroleptic malignant syndrome (NMS) are reviewed, to which the authors add three, and possibly four, new cases seen in Australia, occurring in an estimated 1,250 patients exposed to the drug. The review suggests that typical NMS does occur with clozapine and that its incidence may be as common as with the classic neuroleptics. The features of clozapine-induced NMS may be somewhat different, with fewer extrapyramidal side effects and a lower rise in creatine kinase levels. The occurrence of NMS with clozapine raises important issues with regard to our understanding of the pathophysiology of the syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0028806374&partnerID=8YFLogxK

U2 - 10.1097/00004714-199510000-00010

DO - 10.1097/00004714-199510000-00010

M3 - Article

VL - 15

SP - 365

EP - 371

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 5

ER -